Locations:
Search
Long-awaited efficacy against disability progression in nonrelapsing SPMS appears to be at hand
BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial
No effect on symptom severity or disability, and low prevalence of long COVID
Using multidisciplinary care to address mood changes, mitigate daily stressors
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination
A co-author explains some of the key McDonald criteria revisions
The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial
Meaningful characterization is critical to advancing research and care, review authors contend
Guidance from international committee on differential diagnoses and diagnostic approach
Insights on the decision process for selecting a treatment approach
Advertisement
Advertisement